Switching the Sphingolipid Rheostat in the Treatment of Diabetes and Cancer Comorbidity from a Problem to an Advantage

<div>The S1P<sub>2</sub> receptor modulates hepatic insulin signalling. FTY720 binds to S1P<sub>1,3−5 </sub>receptors and does not impact the normal signalling functions of S1P<sub>2</sub>. S1P<sub>2</sub> has been associated with impaired insulin signalling [<a href="/journals/bmri/2015/165105/#B89">86</a>, <a href="/journals/bmri/2015/165105/#B112">109</a>]. FTY720 is a S1P<sub>1,3−5 </sub>agonist but also acts as a functional antagonist of S1P<sub>1</sub> [<a href="/journals/bmri/2015/165105/#B112">109</a>]. FTY720 does not bind to S1P<sub>2</sub> and therefore does not affect S1P<sub>2</sub> function. In contrast, JTE-013 inhibits S1P<sub>2</sub>.</div>

BioMed Research International

fig2

Figure 2

Figure 2: Switching the Sphingolipid Rheostat in the Treatment of Diabetes and Cancer Comorbidity from a Problem to an Advantage 